title: Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
abstract: Canine hemangiosarcoma (HSA) is a highly malignant tumor for which standard chemotherapy has done little to substantially improve survival. Cyclooxygenase-2 (Cox-2) plays a role in the formation, growth, and metastasis of tumors and inhibitors have demonstrated therapeutic benefit with certain canine cancers. In this prospective study, 21 dogs received adjuvant therapy combining the selective Cox-2 inhibitor deracoxib with doxorubicin, following splenectomy for HSA. The combination was well-tolerated with only low-grade gastrointestinal and hematologic toxicities noted. An overall median survival of 150 days (range; 21 to 1506 days) was noted. Although there was no significant difference in survival based upon stage of disease, dogs with stage III HSA (n = 11) had a median survival of 149 days, which appears to be longer than previously reported. Further studies are warranted to evaluate the potential benefit of Cox-2 inhibitors in the treatment of canine HSA.
authors.affiliation: Centre Vétérinaire Laval, Laval, Quebec, Canada. sakahn1@gmail.com
authors.forename: S Anthony
authors.initials: SA
authors.lastname: Kahn
authors.forename: Christine M
authors.initials: CM
authors.lastname: Mullin
authors.forename: Louis-Philippe
authors.initials: LP
authors.lastname: de Lorimier
authors.forename: Kristine E
authors.initials: KE
authors.lastname: Burgess
authors.forename: Rebecca E
authors.initials: RE
authors.lastname: Risbon
authors.forename: Rogers M
authors.initials: RM
authors.lastname: Fred
authors.forename: Kenneth
authors.initials: K
authors.lastname: Drobatz
authors.forename: Craig A
authors.initials: CA
authors.lastname: Clifford
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D010865:Pilot Projects; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
chemical_list: D000903:Antibiotics, Antineoplastic; D052246:Cyclooxygenase 2 Inhibitors; D004317:Doxorubicin; D013449:Sulfonamides; C471996:deracoxib; D000096926:Benzenesulfonamides